by plexusventures_h3tnl0 | Jan 19, 2017 | Uncategorized
Tokyo, Japan – Plexus Ventures is pleased to announce the successful completion of an out-licensing project on behalf of Cynata Therapeutics Ltd. Plexus provided professional services to Cynata in the out-licensing of its lead product, CYP-001, to FUJIFILM...
by plexusventures_h3tnl0 | Jan 19, 2017 | Uncategorized
London, United Kingdom – Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for...
by plexusventures_h3tnl0 | Nov 8, 2016 | Uncategorized
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce it served as advisor to Mabion S.A. in the out-licensing of Mabion CD20 (Rituximab Biosimilar) European rights to Mylan Ireland Limited. Michael O’Sullivan, Managing Partner of Plexus Ventures’...
by plexusventures_h3tnl0 | Oct 27, 2015 | Uncategorized
Philadelphia, Pennsylvania – Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma. Additional details regarding the transaction, taken from Glenmark’s October 23, 2015 press release are included below:...
Recent Comments